Drug intelligence / Profile preview

Calcixol

Development stage: Unknown
Lead developer: Zaiva Lifesciences
Modality: Small Molecules
Administration: Oral

Overview

**Calcixol** is an oral fixed-dose nutritional supplement marketed by Zaiva Lifesciences for calcium deficiency and bone-health support. Each tablet contains calcium citrate, elemental magnesium supplied as magnesium hydroxide, cholecalciferol, and elemental zinc supplied as zinc sulfate monohydrate. Calcium provides substrate for bone mineralization; cholecalciferol is converted to active vitamin D metabolites that activate the vitamin D receptor and promote intestinal calcium absorption; magnesium and zinc provide supporting mineral nutrition relevant to bone metabolism.

Brand names: Calcixol
Other names: Calcium carbonate + cholecalciferolCalcium + Vitamin D

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Calcixol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calcixol.

Explore the full profile